Literature DB >> 25208066

Immunotherapy: Chemical tricks.

Bianca Nogrady.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 25208066     DOI: 10.1038/513S10a

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  4 in total

1.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.

Authors:  H Dong; G Zhu; K Tamada; L Chen
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

2.  Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Authors:  Charles Butts; Mark A Socinski; Paul L Mitchell; Nick Thatcher; Libor Havel; Maciej Krzakowski; Sergiusz Nawrocki; Tudor-Eliade Ciuleanu; Lionel Bosquée; José Manuel Trigo; Alexander Spira; Lise Tremblay; Jan Nyman; Rodryg Ramlau; Gun Wickart-Johansson; Peter Ellis; Oleg Gladkov; José Rodrigues Pereira; Wilfried Ernst Erich Eberhardt; Christoph Helwig; Andreas Schröder; Frances A Shepherd
Journal:  Lancet Oncol       Date:  2013-12-09       Impact factor: 41.316

3.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

4.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors:  G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

  4 in total
  4 in total

1.  Next-generation molecular therapy in lung cancer.

Authors:  Jun Qian; Pierre P Massion
Journal:  Transl Lung Cancer Res       Date:  2018-02

2.  Expression of MUC1 and CD176 (Thomsen-Friedenreich antigen) in papillary thyroid carcinomas.

Authors:  Xiang-xiang Zhan; Bing Zhao; Chang Diao; Yi Cao; Ruo-chuan Cheng
Journal:  Endocr Pathol       Date:  2015-03       Impact factor: 3.943

3.  Dynamic TF-lncRNA Regulatory Networks Revealed Prognostic Signatures in the Development of Ovarian Cancer.

Authors:  Qiuyan Guo; Junwei Wang; Yue Gao; Xin Li; Yangyang Hao; Shangwei Ning; Peng Wang
Journal:  Front Bioeng Biotechnol       Date:  2020-05-13

4.  Comprehensive analysis of lncRNA-mRNA co-expression patterns identifies immune-associated lncRNA biomarkers in ovarian cancer malignant progression.

Authors:  Qiuyan Guo; Yan Cheng; Tian Liang; Yanan He; Chengcheng Ren; Liyuan Sun; Guangmei Zhang
Journal:  Sci Rep       Date:  2015-12-03       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.